Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cognition Therapeutics and keeping the price target at $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors including the progress in Cognition Therapeutics’ clinical trials and the potential regulatory advancements. The company’s Phase 2 START trial for zervimesine in early Alzheimer’s disease has reached the midpoint of enrollment, with significant backing from the National Institute of Aging. This progress indicates a strong commitment to advancing treatment options for Alzheimer’s, which is a positive indicator for the company’s future prospects.
Additionally, the upcoming end-of-Phase 2 meeting with the FDA for zervimesine in Alzheimer’s disease is a crucial step towards regulatory approval. The company’s efforts to advance zervimesine in dementia with Lewy bodies, including the application for Breakthrough Therapy Designation and the ongoing expanded access program, further strengthen the potential for future success. These developments, combined with the possibility of receiving regulatory clarity and breakthrough status, support the Buy rating as they represent significant milestones that could enhance the company’s market position.